Numinus Wellness Past Earnings Performance

Past criteria checks 0/6

Numinus Wellness's earnings have been declining at an average annual rate of -30.6%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 71.5% per year.

Key information

-30.6%

Earnings growth rate

-1.1%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate71.5%
Return on equity-550.7%
Net Margin-113.5%
Last Earnings Update31 May 2024

Recent past performance updates

Recent updates

Even With A 83% Surge, Cautious Investors Are Not Rewarding Numinus Wellness Inc.'s (TSE:NUMI) Performance Completely

Nov 10
Even With A 83% Surge, Cautious Investors Are Not Rewarding Numinus Wellness Inc.'s (TSE:NUMI) Performance Completely

Not Many Are Piling Into Numinus Wellness Inc. (TSE:NUMI) Stock Yet As It Plummets 33%

Aug 24
Not Many Are Piling Into Numinus Wellness Inc. (TSE:NUMI) Stock Yet As It Plummets 33%

It's Down 33% But Numinus Wellness Inc. (TSE:NUMI) Could Be Riskier Than It Looks

Jun 08
It's Down 33% But Numinus Wellness Inc. (TSE:NUMI) Could Be Riskier Than It Looks

Market Cool On Numinus Wellness Inc.'s (TSE:NUMI) Revenues Pushing Shares 30% Lower

Apr 17
Market Cool On Numinus Wellness Inc.'s (TSE:NUMI) Revenues Pushing Shares 30% Lower

Slammed 27% Numinus Wellness Inc. (TSE:NUMI) Screens Well Here But There Might Be A Catch

Feb 25
Slammed 27% Numinus Wellness Inc. (TSE:NUMI) Screens Well Here But There Might Be A Catch

After Leaping 30% Numinus Wellness Inc. (TSE:NUMI) Shares Are Not Flying Under The Radar

Jan 05
After Leaping 30% Numinus Wellness Inc. (TSE:NUMI) Shares Are Not Flying Under The Radar

Numinus Wellness Inc.'s (TSE:NUMI) Popularity With Investors Is Clear

Apr 17
Numinus Wellness Inc.'s (TSE:NUMI) Popularity With Investors Is Clear

Revenue & Expenses Breakdown

How Numinus Wellness makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSX:NUMI Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 May 2422-26240
29 Feb 2423-27280
30 Nov 2323-28301
31 Aug 2323-30321
31 May 2319-44332
28 Feb 2314-45312
30 Nov 2211-46312
31 Aug 226-45272
31 May 223-28222
28 Feb 223-26202
30 Nov 212-22172
31 Aug 212-19141
31 May 211-14121
28 Feb 211-1390
30 Nov 201-1180
31 Aug 201-1070
31 May 201-1060
29 Feb 200-860
30 Nov 190-750
31 Aug 190-750
31 Aug 183-330

Quality Earnings: NUMI is currently unprofitable.

Growing Profit Margin: NUMI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NUMI is unprofitable, and losses have increased over the past 5 years at a rate of 30.6% per year.

Accelerating Growth: Unable to compare NUMI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUMI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).


Return on Equity

High ROE: NUMI has a negative Return on Equity (-550.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:46
End of Day Share Price 2024/12/24 00:00
Earnings2024/05/31
Annual Earnings2023/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Numinus Wellness Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullMaxim Group
Michael OkunewitchMaxim Group